Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C.J. Langer

1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

The Carbondale, Colorado, Earthquake Swarm of April - May, 1984

Open-File Report
1988English

Related publications

P3.01-30 Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn198 - An Economic Systematic Literature Review (Slr) for Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small-Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Budget Impact of Alectinib in the Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Development of Anaplastic Lymphoma Kinase (ALK) Inhibitors and Molecular Diagnosis in ALK Rearrangement-Positive Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2014English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy